Patrys Limited · ASX:PAB
Patrys — Investor Presentation (October 2011)
20 slides from Patrys's investor presentation, Oct 10, 2011
Slide 1: Investor Presentation October 2011
For personal use only Investor Presentation October 2011 Dr. Marie Roskrow Chief Executive Officer ASX: PAB
Slide 2: Safe Harbour Statement
Safe Harbour Statement For personal use only The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of los
Slide 3: Key Investment Highlights
Key Investment Highlights For personal use only Patrys is an ASX listed, Australian based international biotechnology company focused on the discovery and development of natural human antibody therapeutics for the treatment of cancer Multiple potential blockbuster drugs for cancer, currently in cl
Slide 4: Corporate Overview
Corporate Overview For personal use only KEY STATISTICS – 30 SEPTEMBER 2011 (A$) 1 YEAR SHARE PERFORMANCE ASX Code PAB $0.15 Current share price $0.054 $0.13 Share Price A$ 52 Week High $0.18 $0.11 52 Week Low $0.05 $0.09 Shares on Issue 249,213,898 $0.07 Market Capitalisation $13.5 m $0.05 Cash (30
Slide 5: Pipeline Progress – Past months
Pipeline Progress – Past 12 months For personal use only Patrys has moved from being a preclinical to a clinical-stage oncology company PAT-SM6 Clinical: Phase 1 single-dose melanoma study commenced August 2010 Safe in all treated patients to date Detected presence of PAT-SM6 in tumours of 2 treat
Slide 6: Technology Overview
Technology Overview For personal use only Spleen / lymph nodes Proprietary antibody isolated from multiple capture technology patients 27% IgG 61% 12% IgA IgM 0.10% 40,000 MAbs Captured IgG 14 products 99.90% evaluated to IgM >300 MAbs Passed Screening date Tests approx. 99.9% are IgM’s 6 Non-Confid
Slide 7: Pipeline Overview
Pipeline Overview For personal use only Product Discovery Preclinical Phase I Phase II Phase III PAT-SM6 – Melanoma PAT-SM6 – Solid Tumours - Multiple Myeloma PAT-LM1 – Solid Tumours PAT-SC1 – Gastric Cancer PAT-SC1 – Solid Tumours 4 Undisclosed Abs 4 Others Work conducted at Patrys GmbH, Germany 25
Slide 8: CSL Collaboration
CSL Collaboration For personal use only Agreement signed in January 2010 Covers 4 discovery stage antibodies Driven by CSL interest in disease targets & antibodies Multi-stage/milestone structure First milestone achieved and related payment made to Patrys Status update expected CY2011 8
Slide 9: PAT-SC1 (Gastric Cancer)
PAT-SC1 (Gastric Cancer) For personal use only Pentameric IgM antibody PAT-SC1 Overview First antibody from pipeline evaluated in PAT-SC1 Binding clinical trial to CD55 CD55 Tumour Cell Target: Binds to isoform of CD55 expressed on CD55 multiple types of cancer cells Safe in 51 patients rece
Slide 10: PAT-LM1
PAT-LM1 For personal use only Pentameric IgM antibody Lung Cancer Animal Model Overview Potent killing activity across multiple cancers Binds to NONO protein expressed in 98% of over 200 different patient tumours screened Target: Third party research confirms NONO several critical roles of N
Slide 11: PAT-SM6
PAT-SM6 For personal use only Pentameric IgM antibody Overview Potent killing activity across a range of solid and liquid cancers GRP78 Binds to a protein GRP78 that is expressed in 91% of cancer tissues Target: screened GRP78 Substantial literature reports on role of GRP78 in cancer and pro
Slide 12: PAT-SM6 Melanoma Trial
PAT-SM6 Melanoma Trial For personal use only Single dose, dose escalating, trial of PAT-SM6 in N=9 patients with recurrent in-transit cutaneous melanoma Royal Adelaide Hospital enrolling; ethics approval received for second site in Brisbane Three dose cohorts (0.15, 0.3, 0.6mg/kg), i.v. admini
Slide 13: PAT-SM6 Melanoma Trial
PAT-SM6 Melanoma Trial Pre treatment biopsy Biopsy after PAT-SM6 treatment For personal use only Patient 1 Patient 2 Melanoma patient tumour biopsies were collected before and after treatment with PAT-SM6, fixed in formalin and embedded in paraffin. An antibody specific for PAT-SM6 (PAT-SM6 anti Idi
Slide 14: PAT-SM6 Future Plans
PAT-SM6 Future Plans For personal use only Multiple Myeloma: Phase I/II open label multi-dose trial, relapsed and multi-resistant patients (N=10-12) University of Würzburg Commence 1HCY2012; 12 month study Continuing rolling data Estimated cost - $1m Solid Tumours, including Melanoma: Ph
Slide 15: PAT-LM1 and PAT-SC1 Future Plans
PAT-LM1 and PAT-SC1 Future Plans For personal use only PAT-LM1: Preclinical evaluation including multi-dose toxicology Phase I/II open label, multi-dose trial, stage IV patients with solid tumours Multiple centres across Australia Commence 2HCY2012; 15-18 month study Estimated cost - $5m P
Slide 16: Key Investment Highlights
Key Investment Highlights For personal use only Multiple potential blockbuster drugs for cancer, currently in clinical or late preclinical Exciting Antibody development Pipeline Additional pipeline of early preclinical antibodies against novel cancer targets Collaboration with CSL Ltd involvin
Slide 17: For Further Information
For Further Information For personal use only Contact Details Dr. Marie Roskrow, Chief Executive Officer Roger McPherson, Chief Financial Officer Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com 17
Slide 18: Appendix
For personal use only Appendix 18
Slide 19: Leader in Natural Human Antibodies
Leader in Natural Human Antibodies For personal use only Natural Human Target Preclinical Antibody Clinical Trials Identification Development Technology Ability to develop 40,000 antibodies Technology platform Innovative trial antibodies and move captured & screened allows capture of design provides
Slide 20: Why IgM's?
Why IgM’s? For personal use only IgM’s are the body’s first line of defence as part of the innate immune system Have shown anti-tumour activity in both mice and humans and exhibit therapeutic promise Have an excellent safety profile in humans Specificity of IgM’s potential lead to reduced si